Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Need For Federal Insurance Czar Is Questioned
"Health care overhaul legislation from President Barack Obama"s congressional allies would create a federal insurance czar with sweeping new powers to oversee medical plans nationwide, an idea already drawing fierce criticism," The Associated Press reports. "State insurance commissioners are objecting, saying it would duplicate what they now do without offering any better protection for consumers. Conservatives are calling it a textbook example of a big government mentality."
generic viagra online
Reports From The White House And Kaiser Family Foundation Address Health Care Disparities
Health and Human Services Secretary Kathleen Sebelius and White House Health Czar Nancy Ann DeParle held a discussion of minority health issues at the White House yesterday, where Sebelius "said the Obama administration is committed to addressing the "alarming disparity in the delivery of quality health care"," which she said was necessary to lower costs, the Associated Press reports. The White House also "issued a summary report on minority health care showing that African-Americans are seven times more likely as whites to have HIV/AIDS, that blacks and Hispanics have diabetes rates nearly twice as high as whites, and that black men are 50 percent more likely than whites to have prostate cancer" (Evans, 6/9).
News of the day
Plastics Chemical Retards Growth, Function Of Adult Reproductive Cells
Bisphenol A, a chemical widely used in plastics and known to cause reproductive problems in the offspring of pregnant mice exposed to it, also has been found to retard the growth of follicles of adult mice and hinder their production of steroid hormones, researchers report.
Public Health

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect On Photoreceptors

Neurotech Pharmaceuticals, Inc. announced that the Company"s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments. In both studies, there was a statistically significant (pAbout Retinitis Pigmentosa (RP) Retinitis Pigmentosa (RP) is an inherited disease that causes the retina"s rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP. About NT-501 Neurotech"s lead product, NT-501, consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). CNTF is a growth factor capable of rescuing dying photoreceptors and protecting them from degeneration. NT-501 is designed to continually deliver a therapeutic dose of CNTF into the back of the eye. About Encapsulated Cell Technology Neurotech"s core technology platform is Encapsulated Cell Technology (ECT), a unique technology that allows for the long-term, sustained delivery of therapeutic factors to the back of the eye. ECT implants consist of cells that have been genetically modified to produce a specific therapeutic protein and are encapsulated in a semi-permeable hollow fiber membrane. The diffusive characteristics of the hollow fiber membrane are designed to promote long-term cell survival by allowing the influx of oxygen and nutrients while simultaneously preventing direct contact of the encapsulated cells with the cellular and molecular elements of the immune system. The cells continuously produce the therapeutic protein which diffuses out of the implant at the target site. ECT thereby enables the controlled, continuous delivery of therapeutic factors directly to the retina, bypassing the blood-retina barrier. About Neurotech Pharmaceuticals, Inc. Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases. The Company"s lead product candidate, NT-501, is currently in late-stage clinical development for advanced dry age-related macular degeneration (dry AMD) and retinitis pigmentosa (RP). The Company"s portfolio of product candidates also includes treatments for wet AMD. All of Neurotech"s development programs are based on the Company"s proprietary Encapsulated Cell Technology (ECT). ECT uniquely enables the controlled, continuous delivery of biologics directly to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease. Neurotech Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009